| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Papers In Press, published online ahead of print October 14, 2002
Lineberger Cancer Center, University of North Carolina, Chapel Hill, NC 27599-7295
Corresponding Author: kole{at}med.unc.edu
Overexpression of Bcl-xL, an anti-apoptotic member of the Bcl-2 family, negatively correlates with the sensitivity of various cancers to chemotherapeutic agents. We show here that high levels of expression of Bcl-xL promoted apoptosis of cells treated with an antisense oligonucleotide (5'Bcl-x AS) that shifts the splicing pattern of Bcl-x pre-mRNA from the anti-apoptotic variant, Bcl-xL, to the pro-apoptotic variant, Bcl-xS. This surprising finding illustrates the advantage of antisense-induced modulation of alternative splicing versus downregulation of targeted genes. It also suggests a specificity of the oligonucleotide effects since non-cancerous cells with low levels of Bcl-xL should resist the treatment. 5'Bcl-x AS sensitized cells to several antineoplastic agents and radiation and was effective in promoting apoptosis of MCF7/ADR cells, a breast cancer cell line resistant to doxorubicin via overexpression of the mdr1 gene. Efficacy of 5'Bcl-x AS combined with chemotherapeutic agents in the PC3 prostate cancer cell line may be translated to clinical prostate cancer since recurrent prostate cancer tissue samples expressed higher levels of Bcl-xL than benign prostate tissue. Treatment with 5'Bcl-x AS may enhance the efficacy of standard anti-cancer regimens and should be explored, especially in recurrent prostate cancer.
J. Biol. Chem, 10.1074/jbc.M209236200
Submitted on September 9, 2002
Revised on October 8, 2002
Accepted on October 14, 2002
Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Shkreta, U. Froehlich, E. R. Paquet, J. Toutant, S. A. Elela, and B. Chabot Anticancer drugs affect the alternative splicing of Bcl-x and other human apoptotic genes Mol. Cancer Ther., June 1, 2008; 7(6): 1398 - 1409. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Aartsma-Rus and G.-J. B. van Ommen Antisense-mediated exon skipping: A versatile tool with therapeutic and research applications RNA, October 1, 2007; 13(10): 1609 - 1624. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Zhang, J. J. Peairs, P. Yang, J. Tyrrell, J. Roberts, R. Kole, and G. J. Jaffe The Importance of Bcl-xL in the Survival of Human RPE Cells Invest. Ophthalmol. Vis. Sci., August 1, 2007; 48(8): 3846 - 3853. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Du, J. M. Pollard, and R. A. Gatti Correction of prototypic ATM splicing mutations and aberrant ATM function with antisense morpholino oligonucleotides PNAS, April 3, 2007; 104(14): 6007 - 6012. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Paronetto, T. Achsel, A. Massiello, C. E. Chalfant, and C. Sette The RNA-binding protein Sam68 modulates the alternative splicing of Bcl-x J. Cell Biol., March 26, 2007; 176(7): 929 - 939. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. K. Singh, N. N. Singh, E. J. Androphy, and R. N. Singh Splicing of a Critical Exon of Human Survival Motor Neuron Is Regulated by a Unique Silencer Element Located in the Last Intron Mol. Cell. Biol., February 15, 2006; 26(4): 1333 - 1346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hachem and R. B. Gartenhaus Oncogenes as molecular targets in lymphoma Blood, September 15, 2005; 106(6): 1911 - 1923. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Garneau, T. Revil, J.-F. Fisette, and B. Chabot Heterogeneous Nuclear Ribonucleoprotein F/H Proteins Modulate the Alternative Splicing of the Apoptotic Mediator Bcl-x J. Biol. Chem., June 17, 2005; 280(24): 22641 - 22650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. F. Weber and A. S. Menko The Canonical Intrinsic Mitochondrial Death Pathway Has a Non-apoptotic Role in Signaling Lens Cell Differentiation J. Biol. Chem., June 10, 2005; 280(23): 22135 - 22145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Liao, S. Tang, J. B. Thrasher, T. L. Griebling, and B. Li Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer Mol. Cancer Ther., April 1, 2005; 4(4): 505 - 515. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Syrovets, J. E. Gschwend, B. Buchele, Y. Laumonnier, W. Zugmaier, F. Genze, and T. Simmet Inhibition of I{kappa}B Kinase Activity by Acetyl-boswellic Acids Promotes Apoptosis in Androgen-independent PC-3 Prostate Cancer Cells in Vitro and in Vivo J. Biol. Chem., February 18, 2005; 280(7): 6170 - 6180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Venables Aberrant and Alternative Splicing in Cancer Cancer Res., November 1, 2004; 64(21): 7647 - 7654. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Ittig, S. Liu, D. Renneberg, D. Schumperli, and C. J. Leumann Nuclear antisense effects in cyclophilin A pre-mRNA splicing by oligonucleotides: a comparison of tricyclo-DNA with LNA Nucleic Acids Res., January 15, 2004; 32(1): 346 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Villemaire, I. Dion, S. A. Elela, and B. Chabot Reprogramming Alternative Pre-messenger RNA Splicing through the Use of Protein-binding Antisense Oligonucleotides J. Biol. Chem., December 12, 2003; 278(50): 50031 - 50039. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |
